Partnership with Roche Diagnostics France

image1-24
31 March 2015

Roche Diagnostics France and PrimaDiag announced today they have concluded a joint promotion agreement whose aim is to propose an automation solution for Roche’s  capture of exomes sequencing product range NimbleGen with PrimaDiag’s automation platform ACSIA NGSCaptureEdition.

This agreement is the result of the combined expertises of the two companies, PrimaDiag offers, on one hand, automation of protocole solutions in the field of molecular biology and on the other hand, Roche Diagnostics France furnishes its’ method for liquid phase sequence capturing  allowing for the enrichment of genomic regions of interest.

The automation solution on the ACSIA NGSCapture Edition platform is possible for the capture of exomes for all  the sequencing products in the NimbleGen SeqCap Enrichment System (EZ, Epi, RNA) product range and for the preparation of samples for exomes libraries . The automation allows the capture from 1 to 48 samples and increases productivity while decreasing the quantity of reagents and  consumables that are used during the different steps of a protocol. The automation of the capture of exomes for sequencing reduces the risks of error during the manipulation of the tubes of reagents while increasing the reproducibility of inter-samples. The flow is thus increased and the costs of sequencing are decreased.

“Working with Roche Diagnostics France on the automation of the NimbleGen SeqCap kits is a unique opportunity for PrimaDiag. The quality of Roche’s NimbleGen products is a natural fit with PrimaDiag’s desire to show the efficiency of its ACSIA products solutions as well as  the expertise of their respective teams.

The result of this partnership is the development of automation methods which respect and optimize the intrinsic qualities of the NimbleGen kits.

Through this partnership, Roche Diagnostics France and PrimaDiag put within the reach of all the laboratories an automated solution of high quality for the capture of exomes for sequencing” declared Grégory Meunier, General Manager, PrimaDiag.

“By combining our Roche NimbleGen capture of exomes for sequencing solutions with PrimaDiag’s line of ASCIA automated platforms, we allow researchers to respond to the increased number of samples to be analyzed and also to the increased of the number of genes to be studied and to be detected by sequencing”. Carole Donne-Goussé, Product Manager, Roche Sequencing.

Thanks to this collaboration, this complete and successful solution will allow  customers to benefit from a flexible and simplified workflow.

About PrimaDiag

PrimaDiag, a French company, based at Biocitech (dedicated to Science and  biotechnologies) park  in the Paris area, develops compact robotics platforms for rapid automation of a large variety of biology protocols and in particular for molecular biology protocols.

PrimaDiag began as an engineering consulting firm in October, 2007 and acquired expertise in the domains of robotics, computer science and biology through various projects realized in France and in Europe.

In 2014, with its acquired experience, PrimaDiag launched its new range of ” ACSIA “  products offering turnkey solutions, based on a new concept, for the better part of biological protocols.

The concept has a a set of bases and a set of robotics accessories which can be combined to support a given protocol and managed by a very powerful and user friendly software, PrimaController®II.

Reliable and robust, the ACSIA product line is ideal to prepare of PCR / qPCR, plates, he purification of nucleic acids, the preparation of libraries and the NGS protocol captures as well as any other protocol requiring the handling of liquids.

For more information , please visit  www.primadiag.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit  www.roche-diagnostics.com.

All trademarks used or mentioned in this release are protected by law.

Media contacts Roche Diagnostics France :

Sophie De Leiris : sophie.de_leiris@roche.com
Virginie Lobo : virginie.lobo@roche.com
Eudes De Villiers : eudes.de_villiers@roche.com

Press release translated from the official french version.

Categories: News